Related Experiment Video

Updated: Jun 27, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

Targeted therapies in gastrointestinal stromal tumors

Cristina R Antonescu1

  • 1Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. antonesc@mskcc.org

Seminars in Diagnostic Pathology
|November 19, 2008
PubMed

Insights

Gastrointestinal stromal tumors (GISTs) are driven by KIT activation. While imatinib is effective, resistance emerges, necessitating new targeted therapies for GIST treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Constitutive KIT activation is central to gastrointestinal stromal tumor (GIST) pathogenesis.
  • Imatinib mesylate targets KIT kinase activity, serving as a first-line therapy for advanced GISTs.
  • Treatment failure in wild-type GIST and resistance mechanisms highlight unmet therapeutic needs.

Purpose of the Study:

  • To review current knowledge on targeted therapy for GIST.
  • To discuss the role of KIT signaling in GIST pathogenesis and resistance.
  • To update on diagnostic challenges related to imatinib response and resistance.

Main Methods:

  • Literature review of targeted therapies for GIST.
  • Analysis of KIT signaling pathways in GIST.
  • Discussion of resistance mechanisms and diagnostic pitfalls.

Main Results:

  • KIT exon 11 mutations respond well to imatinib, but wild-type genotypes show higher failure rates.
  • Acquisition of secondary mutations in the kinase domain is a common resistance mechanism.
  • Diagnostic challenges arise from imatinib response and resistance patterns.

Conclusions:

  • Targeted therapy for GIST relies heavily on inhibiting KIT oncogenic activation.
  • Emerging resistance mechanisms necessitate the development of novel therapeutic strategies.
  • Accurate diagnosis and monitoring are crucial for managing GIST patients undergoing targeted therapy.

More Related Videos

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...